Related Experiment Video
Updated: May 16, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Thrombocytopenia, bleeding, and use of platelet transfusions in sick neonates
1National Health Service (NHS) Blood & Transplant/Oxford University Hospitals NHS Trust, Oxford, United Kingdom. simon.stanworth@nhsbt.nhs.uk
Insights
Platelet transfusions are common for premature infants with low platelet counts, but evidence supporting their prophylactic use is lacking. More research is needed to establish safe and effective transfusion guidelines for neonates.
Area of Science:
- Neonatal Medicine
- Hematology
- Pediatric Critical Care
Background:
- Premature infant survival has improved with supportive care, including red blood cell (RBC) transfusions.
- Neonatal thrombocytopenia is frequent in premature infants, linked to intrauterine growth restriction, maternal hypertension, sepsis, or necrotizing enterocolitis.
- The role and efficacy of platelet transfusions in neonates remain controversial, with no clear link established between platelet count and major hemorrhage risk.
Purpose of the Study:
- To evaluate the current practices and evidence base for prophylactic platelet transfusions in premature neonates.
- To highlight the lack of clinical trials defining optimal pretransfusion platelet count thresholds.
- To underscore the need for randomized controlled trials to guide safe and effective platelet transfusion practices in this population.
Main Methods:
- Review of existing literature on neonatal thrombocytopenia and platelet transfusion practices.
- Analysis of current variations in pretransfusion platelet count thresholds across institutions and countries.
- Identification of the absence of recent clinical trials comparing different transfusion thresholds in premature neonates.
Main Results:
- Significant variation exists in platelet transfusion practices and pretransfusion thresholds among hospitals and countries.
- There is a lack of robust clinical trial evidence to support the common prophylactic use of platelet transfusions in premature neonates.
- Cardiorespiratory problems, not platelet count, are primary factors in neonatal intraventricular/periventricular hemorrhage.
Conclusions:
- Current prophylactic platelet transfusion practices in premature neonates lack a strong evidence base.
- Widespread disparities in transfusion thresholds indicate a need for standardized guidelines.
- Randomized controlled trials are essential to determine optimal platelet transfusion strategies for premature infants, given their heavy current use.
Abstract:
Survival rates for infants born prematurely have improved significantly, in part due to better supportive care such as RBC transfusion. The role of platelet transfusions in neonates is more controversial. Neonatal thrombocytopenia is common in premature infants. The primary causal factors are intrauterine growth restriction/maternal hypertension, in which the infant presents with thrombocytopenia soon after birth, and sepsis/necrotizing enterocolitis, which are the common morbidities associated with thrombocytopenia in neonates > 72 hours of age. There is no evidence of a relationship between platelet count and occurrence of major hemorrhage, and cardiorespiratory problems are considered the main etiological factors in the development of intraventricular and periventricular hemorrhage in the neonatal period. Platelet transfusions are used commonly as prophylaxis in premature neonates with thrombocytopenia. However, there is widespread variation in the pretransfusion thresholds for platelet count and evidence of marked disparities in platelet transfusion practice between hospitals and countries. Platelet transfusions are biological agents and as such are associated with risks. Unlike other patient groups, specifically patients with hematological malignancies, there have been no recent clinical trials undertaken comparing different thresholds for platelet transfusion in premature neonates. Therefore, there is no evidence base with which to inform safe and effective practice for prophylactic platelet transfusions. There is a need for randomized controlled trials to define the optimal use of platelet transfusions in premature neonates, who at present are transfused heavily with platelets.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

